Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria

Liver Transplantation

Volumn 20, Issue 11, 2014, Pages 1327-1335

  Parisi, Ioanna ^a   Tsochatzis, Emmanuel ^a   Wijewantha, Hasitha ^a   Rodríuez Perálvarez, Manuel ^a   De Luca, Laura ^a   Manousou, Pinelopi ^a   Fatourou, Evangelia ^a   Pieri, Giulia ^a   Papastergiou, Vassilios ^a   Davies, Neil ^b   Yu, Dominic ^b   Luong, TuVinh ^b   Dhillon, Amar Paul ^b   Thorburn, Douglas ^a   Patch, David ^a   O'Beirne, James ^a   Meyer, Tim ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; ALBUMINOID; BIOLOGICAL MARKER;

ADULT; ALBUMIN BLOOD LEVEL; ALCOHOL ABUSE; ARTICLE; ARTIFICIAL EMBOLISM; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHILD PUGH SCORE; CHRONIC HEPATITIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; INFLAMMATION BASED INDEX; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MILAN CRITERIA; MULTIMODALITY CANCER THERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUTROPHIL; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; TUMOR NECROSIS; BLOOD; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; IMMUNOLOGY; LIVER; LIVER NEOPLASMS; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PROSPECTIVE STUDY; THROMBOCYTE COUNT; TUMOR RECURRENCE;

ALBUMINS; BIOMARKERS; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLATELET COUNT; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 84912058004     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23969     Document Type: Article

References (31)

1. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211.
2. Tsochatzis EA, Germani G, Burroughs AK. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol 2010;37:89-93.
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
4. Germani G, Theocharidou E, Adam R, Karam V, Wendon J, O'Grady J, et al. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol 2012;57:288-296.
5. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008;143:182-188.
6. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al.; for Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986-994 e3; quiz e14-e15.
7. Yoshizumi T, Ikegami T, Yoshiya S, Motomura T, Mano Y, Muto J, et al. Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. Hepatol Res 2013;43:709-716.
8. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013;59:1193-1199.
9. Tsochatzis E, Garcovich M, Marelli L, Papastergiou V, Fatourou E, Rodriguez-Peralvarez ML, et al. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int 2013;33:944-949.
10. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
11. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The Glasgow prognostic score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer 2013;13:52.
12. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008;32:1757-1762.
13. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011;47:2633-2641.
14. Malietzis G, Giacometti M, Askari A, Nachiappan S, Kennedy RH, Faiz OD, et al. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann Surg 2014;260:287-292.
15. Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, et al. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol 2012;57:1013-1020.
16. Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013;108:1252-1259.
17. Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, et al. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer 2013;13:78.
18. Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int 2014;27:32-41.
19. Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, et al. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 2011;91:1279-1285.
20. Halazun KJ, Hardy MA, Rana AA, Woodland DC 4th, Luyten EJ, Mahadev S, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009;250:141-151.
21. Lee DY, Hong SW, Chang YG, Lee WY, Lee B. Clinical significance of preoperative inflammatory parameters in gastric cancer patients. J Gastric Cancer 2013;13:111-116.
22. Tomita M, Shimizu T, Ayabe T, Nakamura K, Onitsuka T. Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected nonsmall cell lung cancer. Anticancer Res 2012;32:3535-3538.
23. Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 2012;48:1977-1987.
24. Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, et al. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol 2011;54:497-505.
25. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013;58:58-64.
26. McNally ME, Martinez A, Khabiri H, Guy G, Michaels AJ, Hanje J, et al. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Surg Oncol 2013;20:923-928.
27. Zheng YB, Zhao W, Liu B, Lu LG, He X, Huang JW, et al. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev 2013;14:5527-5531.
28. Lagadinou M, Solomou EE, Velissaris D, Theodorou GL, Karakatza M, Gogos CA. Alterations in T-lymphocyte subpopulations in patients with complicated liver cirrhosis. Diagn Microbiol Infect Dis 2013;75:348-356.
29. + T cells affect the prognosis of hepatocellular carcinoma patients. Digestion 2012;86:329-337.
30. Huang ZL, Luo J, Chen MS, Li JQ, Shi M. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Intervent Radiol 2011;22:702-709.
31. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.